AstraZeneca’s Imfinzi Gains CHMP Backing as First Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer in the EU AstraZeneca has announced a significant regulatory milestone for its cancer immunotherapy, Imfinzi (durvalumab), with…
AbbVie Highlights Expanding Oncology Pipeline at ASCO 2025 with New Data Across Challenging Solid Tumors and Blood Cancers AbbVie has announced a significant presence at the upcoming 2025 American Society…
Eli Lilly to Acquire SiteOne Therapeutics in $1 Billion Deal to Advance Non-Opioid Pain Therapy In a strategic move aimed at strengthening its neuroscience and pain management portfolio, Eli Lilly…
Lupin and SteinCares Forge Strategic License and Supply Agreement to Commercialize Ranibizumab Biosimilar Across Latin America Global pharmaceutical leader Lupin Limited (Lupin) has officially announced the signing of a significant…
WHO Launches Landmark Guideline to Bridge Global Gaps in Access to Controlled Medicines In a bold step toward improving global health equity, the World Health Organization (WHO) unveiled a new…
Eisai’s Lemborexant (DAYVIGO®) Receives Regulatory Approval in China for the Treatment of Insomnia Eisai Co., Ltd., a leading global pharmaceutical company headquartered in Tokyo and led by CEO Haruo Naito,…
Partnering for Progress: How Astellas and the Pompe Disease Community Are Shaping the Future Together Pompe disease is a rare, inherited, and progressively debilitating disorder that profoundly affects the lives…
Practice-Changing Data, Innovative Modalities, and Global Impact Headline ASCO 2025 The oncology community is converging in Chicago this week for the highly anticipated 2025 Annual Meeting of the American Society…
U.S. Vaccine Innovation at Risk: How Four Biotechs Are Being Squeezed by Shifting Policies, Funding Cuts, and Regulatory Changes As the World Health Organization (WHO) sets a new course for…
World Health Assembly Approves Extension of Global Digital Health Strategy to 2027 and Greenlights Next Phase for 2028–2033 In a landmark decision underscoring the accelerating global commitment to digital health,…
Cullinan Therapeutics and Taiho Highlight Promising Phase 2b Results of Zipalertinib in Advanced EGFR ex20ins NSCLC at ASCO 2025 Cullinan Therapeutics,in collaboration with Taiho Pharmaceutical Co., Ltd., and its U.S.…
Astellas and Pfizer Showcase Five-Year Survival Benefits of XTANDI in Metastatic Hormone-Sensitive Prostate Cancer at ASCO 2025 In a pivotal milestone for prostate cancer treatment, Astellas Pharma Inc. and Pfizer…